Showing results (161-170 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Prognostic value of size of lymph node metastases in patients with cutaneous melanomaA C Buzaid, L A Tinoco, D Jendiroba, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyK Itoh, K Hayakawa, M A Salmeron, et al.
Annals of Surgery|December 1, 1984
Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatmentM M Urist, C M Balch, S J Soong, et al.
Cancer Treatment Reviews|June 1, 1989
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer CenterD R Parkinson, M Talpaz, K H Lee, et al.
American Journal of Surgery|October 17, 1998
Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissectionR J Bold, P F Mansfield, D H Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Sentinel lymph node biopsy for melanoma: controversy despite widespread agreementK M McMasters, D S Reintgen, M I Ross, et al.
In Vivo (Athens, Greece)|November 1, 1991
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapiesK Itoh, C M Balch, J L Murray, et al.
Annals of Surgical Oncology|January 5, 2002
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsyS Dessureault, S J Soong, M I Ross, et al.
Annals of Surgery|September 1, 1993
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trialC M Balch, M M Urist, C P Karakousis, et al.
Cancer|January 1, 1995
A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanomaM K Wallack, M Sivanandham, C M Balch, et al.
Pageof 19